Product Name: Chk2Selectide
Product Number: PE-01BGT95
Size: 200 µg      Price:40.00
1 mg      $US80.00
5 mg      187.00
Peptide Name: Chk2Selectide

Product Use: For assaying the phosphotransferase activity of Checkpoint protein-serine kinase 2 (UniProt ID O96017).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: GLFRAKSQRRKG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Molecular Mass Calculated: 1576.9 Da

Peptide Purity Percent after Synthesis and Purification: >90

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: Chk2

Scientific Background: Chk2 (CHEK2) is a protein-serine/threonine kinase of the CAMK group and RAD53 family. It is required for cell cycle arrest, activation of DNA repair, and the promotion of apoptosis in response to double-stranded breaks in DNA. Chk2 is activated through phosphorylation by ATM and ATR at T68. It is activated by phosphorylation at T68 by MLTK in response to replication blocks and DNA damage; the response to DNA damage occurs in an ataxia telangiectasia mutated (ATM)-dependent manner. It is also activated by phosphorylation at S19, T26, S28, S33, S35, T383, T387 and S516. The effects of Chk2 are mediated through the phosphorylation and inhibition of various downstream effectors, including CDC25A, CDC25B, and CDC25C. In addition, Chk2 phosphorylates p53 and BRCA to mediate cell cycle arrest in response to DNA damage. This kinase shows high variability in human tissue distribution with the highest levels detected in spleen and tonsils, and is notably absent in brain and spinal cord. Orthologues of Chk2 are amongst the most highly conserved protein kinases in animals, plants, fungi and unicellular eukaryotes. Expression of wild-type Chk2 leads to increased p53 stabilization after DNA damage, whereas expression of a dominant-negative Chk2 mutant abrogated both phosphorylation of p53 on S20 and p53 stabilization. Chk2 has been linked with the development of Li-Fraumeni Syndrome 2 (LFS2), breast, colon, and prostate cancers, and osteosarcomas.